

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心璋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

**VOLUNTARY ANNOUNCEMENT
SUPSELEK MICROCATHETER WAS
GRANTED CLEARANCE BY THE FDA**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The Company is pleased to announce that the Food and Drug Administration (“**FDA**”) of the United States of America has recently granted section 510k clearance pursuant to the Food, Drug and Cosmetic Act in relation to the Company’s SupSelek™ Microcatheter.

As of the date of this announcement, the Company has obtained section 510k clearance from the FDA on two products, including SupSelek™ Microcatheter and Fullblock™ Balloon Guiding Catheter. The Company will continue to pursue clearances and registrations of its products abroad.

There is no assurance that either SupSelek™ Microcatheter or Fullblock™ Balloon Guiding Catheter will ultimately be successfully marketed and/or commercialized by the Company. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
Wang Guohui
Chairman of the Board

Shanghai, February 24, 2022

As at the date of this announcement, the executive Directors are Mr. Wang Guohui and Ms. Zhang Kun; the non-executive Directors are Mr. Ding Kui, Mr. Chen Gang and Mr. Ouyang Xiangyu; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.